Washington State Makes Progress on Opioid Crisis as Federal Policies Threaten to Unravel Gains

Travis Gardner, 51, sits in a recliner at Seattle's newest addiction treatment facility while a nurse prepares his monthly buprenorphine injection—the medication that has finally allowed him to stop using fentanyl after years of homelessness. The ORCA Center, a 24-hour substance use treatment clinic in Pioneer Square, represents Washington state's latest innovation in addressing the opioid epidemic: walk-in access until 11 p.m., emergency transport partnerships, cupboards stocked with instant noodles and blankets, and most critically, on-site access to gold-standard medications.

But the day before Gardner's visit, clinic staff had to turn away a different patient seeking identical treatment. The issue wasn't medical—it was bureaucratic. The patient carried out-of-state public insurance, a complication that psychiatric nurse supervisor Aaron Billick used to resolve with a quick phone call to a county hotline. Now, with call volumes up 30% in early 2026 due to sweeping changes in Medicaid eligibility, that same fix can take hours or prove impossible entirely.

"We have to send her down the road to this other clinic," Billick said, "and hope that she makes it."

The contrast between these two patients—one receiving potentially life-saving care, another turned away—illustrates the inflection point facing Washington state's opioid response as promising public health gains collide with federal policy shifts threatening to upend recent progress.

Measurable Progress Built on Innovation

Washington state recorded a more than 12% decline in opioid-related overdose deaths in 2025, continuing a national trend that has seen drug overdose deaths fall nearly 20% in the year ending October 2025, according to the Centers for Disease Control and Prevention. In King County, which includes Seattle, fentanyl was involved in an estimated 707 deaths last year—still stubbornly high but representing the continuation of a downward trajectory after the epidemic peaked locally.

The declines reflect hard-won public health innovations that didn't exist before the fentanyl crisis. King County distributed close to 80,000 naloxone kits through food banks, emergency shelters, supportive housing buildings, and five vending machines in 2024. A county-operated hotline offering same-day buprenorphine prescriptions proved so successful—generating nearly 2,000 new prescriptions in 2024 and 2025—that it expanded statewide in January 2026.

Access to medication for opioid use disorder has grown substantially: 55,583 Washington residents received a buprenorphine prescription in 2024, up from 44,977 in 2018, a nearly 24% increase, according to state Department of Health data analyzed by Dr. Caleb Banta-Green, director of the University of Washington's Center for Community-Engaged Drug Education, Epidemiology and Research.

Treatment options for people experiencing homelessness—who accounted for almost half of King County's fatal overdoses during the epidemic's peak—have expanded in both scope and sophistication. The ORCA Center, operated by Downtown Emergency Service Center and funded through a combination of local, state, and federal dollars, accepts emergency transport patients 24 hours a day and offers walk-in hours from 9 a.m. to 11 p.m. daily. Someone could arrive seeking a buprenorphine prescription at 10 p.m. and leave with medication, a plan, and connection to ongoing support.

Since opening in September 2025, the center has logged more than 300 post-overdose visits, nearly 3,000 walk-ins, and helped more than 370 clients initiate opioid use disorder medications, according to Dr. Callan Fockele, the center's senior medical lead.

An estimated 10% of the county's emergency responses to suspected opioid overdoses now bring people to the ORCA Center rather than hospital emergency departments, which Jon Ehrenfeld—who leads a special unit within the Seattle Fire Department responding to overdoses—describes as poorly suited to connecting people with long-term care due to hectic conditions and pressure to move patients through quickly.

"Here they can quickly get comfort medications and medications to address their symptoms," Ehrenfeld said, "at which point that really makes the rapport building much easier."

For Gardner, the clinic and the day center in which it's located have become "a home away from home." The treatment he receives, combined with placement in supportive housing, has allowed him to envision a different future. "To be able to look forward and have a purpose again, belonging to something," he said.

Federal Headwinds Already Disrupting Care

All these gains face threats from overlapping federal policy changes that health officials describe as potentially catastrophic.

A sweeping overhaul of Medicaid eligibility, included in President Donald Trump's tax cut and spending legislation passed last July, will soon require most enrollees to demonstrate employment—a steep barrier for people in early recovery from substance use disorders. While the new rules include exemptions for some vulnerable groups, including those experiencing addiction, experts fear the process of qualifying for exemptions will itself become a barrier discouraging people from seeking or maintaining coverage.

"If it's going to be onerous for patients and clinics to make use of that exemption, and if people will be at risk of losing their state insurance as a result, that really worries me," said Dr. Jamie Darnton, associate medical director at Evergreen Treatment Services, a nonprofit serving people with opioid addiction.

Medicaid represents the nation's largest provider of mental health and substance use disorder insurance coverage. Changes to the program threaten access to treatment for the most vulnerable populations precisely when outcomes data suggest current approaches are working.

A federal executive order signed by Trump last summer aims to slash funding for programs offering harm reduction supplies like sterile syringes while simultaneously ramping up involuntary treatment, including long-term institutionalization, for people with substance use disorders who lack stable housing.

In Washington, people can already be detained involuntarily for substance use care under Ricky's Law, which passed in 2016 and went into effect two years later. As of summer 2025, state data show three facilities operating 45 beds for such care. A federal push toward involuntary treatment represents a sharp departure from the voluntary, harm-reduction-focused approach that Washington officials credit with recent mortality declines.

"That we're going to subject folks who are more vulnerable to something where we know carries harm with it, it's quite shocking to me," said Susan Collins, a clinical psychologist and co-director of the Harm Reduction Research and Treatment Center at the University of Washington, noting that research shows involuntary treatment is less safe and effective than voluntary care while raising civil liberties concerns.

The impacts are no longer theoretical. Calls to the county-run insurance assistance hotline that Billick previously relied on to resolve coverage issues within minutes jumped 30% in the first three months of 2026 compared with the same period in 2025, according to county data. A Public Health - Seattle & King County spokesperson said demand surged "in large part because of all the changes to Medicaid."

Injectable buprenorphine formulations—which keep patients safe from overdosing for weeks at a time—are available to patients enrolled in Washington's Medicaid program at the ORCA Center. But when patients arrive with out-of-state Medicaid coverage, staff are increasingly forced to refer them elsewhere rather than provide immediate treatment.

The bureaucratic barriers disproportionately affect the populations most vulnerable to fatal overdoses: people without stable housing, those cycling between states, individuals whose chaotic lives make navigating complex insurance systems nearly impossible even when assistance is theoretically available.

A Fragile Inflection Point

Washington's recent progress illustrates what becomes possible when barriers to evidence-based treatment are systematically removed. Expanded naloxone distribution keeps people alive long enough to seek recovery. Same-day prescribing hotlines eliminate the gap between deciding to pursue treatment and accessing medication. Low-barrier clinics like the ORCA Center meet people where they are rather than demanding they navigate Byzantine systems before receiving help.

But the progress remains fragile, dependent on sustained funding streams and regulatory environments that prioritize voluntary, medication-based treatment over punitive or coercive approaches.

"We are way before most of the country in terms of innovating and providing these novel models of care," Banta-Green said. "It's possible it could all be paused or even slowed or even moved backwards due to federal discretionary funding issues."

Fatal fentanyl overdoses in Washington remain stubbornly high despite declines—in February 2026, the drug killed approximately two King County residents each week, and the statewide death count, while 12% lower than 2024, still exceeds the toll recorded in 2022. People without stable housing continue to account for a disproportionate share of deaths: 363 King County residents living outside, in shelters, temporary housing, or supportive housing died from fentanyl overdoses in 2025.

"The bottom line," Banta-Green said, "is that we still have a major, major issue with fentanyl overdose."

When Gardner learned that fatal fentanyl overdoses are decreasing statewide, he nodded in surprise. "I don't know the numbers," he said. "I just hear about my friends dying."

The gap between statistical progress and lived experience underscores both how far Washington has come and how much further remains. Whether the state can sustain its recent gains—much less continue building on them—increasingly depends on federal policy decisions being made far from the Pioneer Square clinic where nurses sterilize arms for monthly injections, cupboards stay stocked with instant noodles, and people like Gardner find something they haven't had in years: the ability to look forward.

Brad Finegood, strategic adviser for behavioral health at Public Health - Seattle & King County, framed the moment as both accomplishment and challenge. "We're in this mode now of continuing to innovate and continuing to get services out there for people who are at risk and disproportionately impacted."

Whether federal policy allows that innovation to continue, or forces Washington to send more patients "down the road" and hope they make it, will help determine how many people die from fentanyl overdoses in 2026—and whether the state's recent progress marks a durable turning point or a brief reprieve.